BIOMAT Database Logo BIOMAT Database Logo

[Treatment of chronic portal-systemic encephalopathy with lactulose (synthetic disaccharide: one molecule of galactose and one of fructose)]. 1972

E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011168 Portal System A system of vessels in which blood, after passing through one CAPILLARY BED, is conveyed through a second set of capillaries before it returns to the systemic circulation. It pertains especially to the hepatic portal system. Portal Systems,System, Portal,Systems, Portal
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004187 Disaccharides Oligosaccharides containing two monosaccharide units linked by a glycosidic bond. Disaccharide
D005260 Female Females
D005632 Fructose A monosaccharide in sweet fruits and honey that is soluble in water, alcohol, or ether. It is used as a preservative and an intravenous infusion in parenteral feeding. Levulose,Apir Levulosa,Fleboplast Levulosa,Levulosa,Levulosa Baxter,Levulosa Braun,Levulosa Grifols,Levulosa Ibys,Levulosa Ife,Levulosa Mein,Levulosado Bieffe Medit,Levulosado Braun,Levulosado Vitulia,Plast Apyr Levulosa Mein,Levulosa, Apir,Levulosa, Fleboplast
D005690 Galactose An aldohexose that occurs naturally in the D-form in lactose, cerebrosides, gangliosides, and mucoproteins. Deficiency of galactosyl-1-phosphate uridyltransferase (GALACTOSE-1-PHOSPHATE URIDYL-TRANSFERASE DEFICIENCY DISEASE) causes an error in galactose metabolism called GALACTOSEMIA, resulting in elevations of galactose in the blood. D-Galactose,Galactopyranose,Galactopyranoside,D Galactose

Related Publications

E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
Treatment of chronic portal-systemic encephalopathy with lactulose.
April 1966, Lancet (London, England),
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
[Lactulose treatment in three patients with chronic portal-systemic encephalopathy].
April 1972, Naika hokan. Japanese archives of internal medicine,
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
Control of chronic portal-systemic encephalopathy by lactulose.
May 1969, Gut,
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
Long-term treatment of portal-systemic encephalopathy with lactulose.
May 1969, Australasian annals of medicine,
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.
August 1988, Journal of hepatology,
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
[Treatment of chronic porto-systemic encephalopathy with lactulose].
April 1969, Schweizerische medizinische Wochenschrift,
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
Emergency treatment of portal-systemic encephalopathy with lactulose enemas. A controlled study.
January 1979, Acta clinica Belgica,
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial.
August 1969, The New England journal of medicine,
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature.
August 1971, The American journal of medicine,
E Cassi, and E Sala, and R Beretta, and A Colombo, and L Cova, and S Ezechieli, and E Malacco, and G Massarotti, and C Pagani
The use of lactulose in portal-systemic encephalopathy.
February 1978, Connecticut medicine,
Copied contents to your clipboard!